Atria Oyj

Quarterly Report • Nov 1, 2013

INTERIM REPORT OF ATRIA PLC 1 JANUARY – 30 SEPTEMBER 2013

Arrangements in Atria Russia weighed down performance

1 January – 30 September 2013

• Atria Russia will discontinue primary pork production and its Moscow-based production operations. As a result, it recognised impairments totalling EUR 23.0 million.

• Atria lowered its EBIT forecast due to the non-recurring costs of its Russian business operations.

• Consolidated EBIT was EUR 9.1 million (EUR 22.4 million) and EBIT without non-recurring items amounted to EUR 24.4 million (EUR 22.4 million).

• Consolidated net sales totalled EUR 1,050.4 million (EUR 982.9 million).

• Atria Finland's net sales grew by EUR 62.7 million, totalling EUR 660.8 million (EUR 598.1 million).

• Atria Finland's EBIT was EUR 23.8 million (EUR 25.5 million) and EBIT without non-recurring items amounted to EUR 22.7 million (EUR 25.5 million).

• Atria Scandinavia's EBIT was EUR 6.5 million (EUR 6.3 million) and EBIT without non-recurring items amounted to EUR 7.4 million (EUR 6.3 million).

• Atria Russia's EBIT was EUR -19.1 million (EUR -4.7 million) and EBIT without non-recurring items amounted to EUR -3.7 million (EUR -4.7 million).

• Atria Baltic's EBIT was EUR -0.1 million (EUR -1.3 million).

• The Group's equity ratio was 40.9 per cent (31 December 2012: 41.5%)

1 July – 30 September 2013

• Atria Russia will discontinue primary pork production and its Moscow-based production operations. As a result, it recognised impairments totalling EUR 23.0 million.

• Atria lowered its EBIT forecast due to the non-recurring costs of its Russian business operations.

• Consolidated net sales totalled EUR 358.4 million (EUR 341.1 million) and EBIT was EUR -1.8 million (EUR

16.6 million). EBIT without non-recurring costs amounted to EUR 14.6 million (EUR 16.6 million).

• Atria Finland's net sales grew by EUR 19.7 million, totalling EUR 224.8 million (EUR 205.1 million).

• Atria Scandinavia's EBIT was EUR 4.7 million (EUR 4.4 million). EBIT without non-recurring costs amounted to EUR 5.6 million (EUR 4.4 million).

• Atria Russia's EBIT was EUR -16.4 million (EUR 0.6 million). EBIT without non-recurring costs amounted to EUR -0.9 million (EUR 0.6 million).

• Atria Baltic's EBIT was positive EUR 0.3 million (EUR -0.4 million).

	Q3	Q3	Q1–Q3	Q1–Q3
EUR million	2013	2012	2013	2012	2012
Net sales	358.4	341.1	1,050.4	982.9	1,343.6
EBIT	-1.8	16.6	9.1	22.4	30.2
EBIT, %	-0.5	4.9	0.9	2.3	2.2
Profit before taxes	-5.0	13.1	-0.2	12.9	18.9
Earnings per share, EUR	-0.54	0.31	-0.48	0.17	0.35
Non-recurring items*	-16.3	0.0	-15.2	0.0	-0.5

*Non-recurring items which are included in the reported EBIT.

Review 1 July – 30 September 2013

Atria Group's net sales for July–September totalled EUR 358.4 million (EUR 341.1 million), up by EUR 17.3 million year-on-year. During the period under review, Atria recognised EUR 23.0 million of non-recurring costs for its Russian business operations. Of this, EUR 15.4 million was allocated to EBIT. Furthermore, an impairment of EUR 0.9 million was recognised for the Scandinavian business operations due to an asset held for sale. Consolidated EBIT weakened by EUR 18.4 million compared to the previous year, standing at EUR -

1.8 million (EUR 16.6 million). EBIT without non-recurring costs decreased slightly to EUR 14.6 million (EUR 16.6 million).

Atria Finland's net sales for July–September totalled EUR 224.8 million (EUR 205.1 million), up by EUR 19.7 million year-on-year. EBIT was EUR 9.8 million (EUR 12.5 million), down by EUR 2.7 million year-on-year. During the period under review, net sales grew in all sales channels. Fiercer price competition in retail products at the end of the quarter, low export prices and the high prices of meat raw materials weighed down the EBIT.

Atria Scandinavia's net sales for July–September totalled EUR 99.7 million (EUR 100.1 million), down by EUR 0.4 million year-on-year. In the local currencies, net sales increased by 2.8 per cent year-on-year. EBIT was EUR 4.7 million (EUR 4.4 million). EBIT includes non-recurring costs of EUR 0.9 million resulting from the impairment of an asset held for sale. The positive performance is due to the improved sales structure and stable raw material prices.

Atria Russia's net sales for July–September totalled EUR 32.0 million (EUR 33.9 million). In the local currency, net sales increased by 2.8 per cent year-on-year. EBIT was EUR -16.4 million (EUR 0.6 million). Atria Russia recognised non-recurring impairments totalling EUR 23.0 million, EUR 15.4 million of which was allocated to EBIT. Of the write-downs, EUR 14.3 million was allocated to fixed assets, EUR 7.6 million to deferred tax assets and EUR 1.1 million to other assets. EBIT without non-recurring costs amounted to EUR -0.9 million (EUR 0.6 million). EBIT without non-recurring costs for July–September was negative due to the poor profitability of primary production. It is estimated that the discontinuation of the unprofitable primary production and the Moscow-based production operations will generate annual cost savings of about EUR 6 million compared to 2013. The cost savings will be fully realised as of the beginning of 2015.

Atria Baltic's net sales for July–September totalled EUR 8.5 million (EUR 8.4 million). Thanks to efficiency improvement measures, EBIT improved by EUR 0.7 million to EUR 0.3 million (EUR -0.4 million) year-on-year.

Review 1 January – 30 September 2013

Atria Group's net sales for January–September totalled EUR 1,050.4 million (EUR 982.9 million), up by EUR 67.5 million year-on-year. During the period under review, Atria recognised EUR 23.0 million of non-recurring costs for its Russian business operations. Of this, EUR 15.4 million was allocated to EBIT. Furthermore, an impairment of EUR 0.9 million was recognised for the Scandinavian business operations due to an asset held for sale. A non-recurring profit of EUR 1.1 million resulting from the reversal of an impairment charge on a property that had been for sale was recognised in Finland. Consolidated EBIT weakened by EUR 13.3 million compared to the previous year, standing at EUR 9.1 million (EUR 22.4 million). EBIT without non-recurring items amounted to EUR 24.4 million (EUR 22.4 million).

In March, Atria issued a fixed-interest bond worth EUR 50 million. The funds were used for refinancing and for the Group's general financing needs. The loan period is five years and a coupon rate of 4.375 per cent is payable on the loan. The bonds are publicly traded on the NASDAQ OMX Helsinki Ltd stock exchange.

The Group's free cash flow for the period under review (operating cash flow - cash flow from investments) was EUR 20.7 million (EUR -1.5 million), and net liabilities were EUR 343.8 million (EUR 417.8 million).

Atria Finland's net sales for January–September totalled EUR 660.8 million (EUR 598.1 million), up by EUR 62.7 million year-on-year. EBIT was EUR 23.8 million (EUR 25.5 million), down by EUR 1.7 million year-onyear. EBIT includes a non-recurring profit of EUR 1.1 million resulting from the reversal of an impairment charge on a property that had been for sale in Forssa. Fiercer price competition at the end of the period under review, high raw material prices in Finland and persistently low export prices weighed down the EBIT.

Atria Scandinavia's net sales for January–September totalled EUR 292.0 million (EUR 284.6 million), up by EUR 7.4 million year-on-year. In the local currency, net sales grew by 1.7 per cent year-on-year. EBIT was EUR 6.5 million (EUR 6.3 million). EBIT includes non-recurring costs of EUR 0.9 million resulting from the

impairment of an asset held for sale. The positive development of EBIT was due to the more stable raw material prices and improved sales structure.

Atria Russia's net sales for January–September totalled EUR 90.8 million (EUR 93.5 million). In the local currency, net sales grew by 1.8 per cent year-on-year. EBIT was EUR -19.1 million (EUR -4.7 million). Atria Russia recognised non-recurring impairments totalling EUR 23.0 million, EUR 15.4 million of which was allocated to EBIT. Of the write-downs, EUR 14.3 million was allocated to fixed assets, EUR 7.6 million to deferred tax assets and EUR 1.1 million to other assets. EBIT without non-recurring costs amounted to EUR -3.7 million (EUR -4.7 million). The result for industrial operations improved thanks to efficiency improvement measures. EBIT without non-recurring costs was negative due to the poor profitability of primary production. It is estimated that the discontinuation of the unprofitable primary production and the Moscow-based production operations will generate annual cost savings of about EUR 6 million compared to 2013. The cost savings will be fully realised as of the beginning of 2015.

Atria Baltic's net sales for January–September totalled EUR 25.0 million (EUR 25.4 million), down by EUR 0.4 million year-on-year. EBIT was EUR -0.1 million (EUR -1.3 million), up by EUR 1.2 million year-on-year.

Key indicators

EUR million	30.9.13	30.9.12	31.12.12
Equity/share, EUR	14.26	15.07	15.15
Interest-bearing liabilities	361.0	425.8	370.5
Equity ratio, %	40.9	39.4	41.5
Gearing, %	88.7	99.2	85.9
Net gearing, %	84.5	97.4	84.3
Gross investments in fixed assets	29.2	41.2	56.2
Gross investments, % of net sales	2.8	4.2	4.2
Average number of personnel	4,688	4,927	4,898

Atria Finland 1 January – 30 September 2013

	Q3	Q3	Q1–Q3	Q1–Q3
EUR million	2013	2012	2013	2012	2012
Net sales	224.8	205.1	660.8	598.1	819.5
EBIT	9.8	12.5	23.8	25.5	36.5
EBIT, %	4.4	6.1	3.6	4.3	4.5
Non-recurring items*	0.0	0.0	1.1	0.0	-0.5

*Non-recurring items which are included in the reported EBIT.

Atria Finland's net sales for July–September totalled EUR 224.8 million (EUR 205.1 million), up by EUR 19.7 million year-on-year. EBIT was EUR 9.8 million (EUR 12.5 million), down by EUR 2.7 million year-on-year. During the period under review, net sales grew in all sales channels: retail trade, Food Service customers as well as export and wholesale market. According to Atria's own estimate, its market share in the retail trade improved to approximately 28 per cent. Fiercer price competition in retail products at the end of the quarter, low export prices and the high prices of meat raw materials weighed down the EBIT.

Net sales for January–September increased by EUR 62.7 million to EUR 660.8 million (EUR 598.1 million). EBIT for January–September was EUR 23.8 million (EUR 25.5 million), down by EUR 1.7 million year-on-year. EBIT includes a non-recurring profit of EUR 1.1 million resulting from the reversal of an impairment charge on a property that had been for sale in Forssa. Fiercer price competition at the end of the period under review, high raw material prices in Finland and persistently low export prices weighed down the EBIT.

Atria Plc and Saarioinen Oy signed a preliminary agreement in July under which Atria will purchase Saarioinen's procurement, slaughtering and cutting operations for beef, pork and chicken. The deal will transfer all of Saarioinen's chicken production machinery and equipment as well as its chicken production building and site in Sahalahti (Kangasala) to Atria. Atria will also acquire the Jyväbroiler brand. In addition, Atria will take possession of all of the machinery and equipment in the Jyväskylä slaughterhouse. In conjunction with the deal, Atria and Saarioinen will sign an agreement concerning meat deliveries from Atria to Saarioinen. The personnel of Saarioinen's procurement, slaughtering and cutting operations will move to Atria as continuing employees, and Atria will continue its industrial operations in Jyväskylä and Sahalahti. The business operations covered by the deal employ about 400 people. Due to the acquisition Atria's net sales are expected to grow by about EUR 70 million annually. It is estimated that the deal will be finalised during the first quarter of 2014 at the latest. The deal is subject to the approval of the Finnish Competition and Consumer Authority.

The transfer of convenience food production from Karkkila to the Nurmo plant has progressed as planned and is expected to generate annual cost savings of about EUR 1.0 million, which will be fully realised as of the beginning of 2014.

The projects in Atria's Handprint programme are progressing according to plan. Atria continues to invest in the transparency of its production chain and the traceability of its products. For Christmas, Atria will launch a traceable Christmas ham, with the name of the farm indicated on the packaging.

The results of the Early Caring project, which was launched in 2009, are now visible on many fronts. The average retirement age for Atria's employees has increased to 63.2 years. In 2009, it was 60.5 years. The positive development is due to the systematic work carried out together with the personnel in order to improve well-being at work. According to statistics published in the summer by the Finnish Centre for Pensions, the average retirement age for Finns is 60.9 years.

Atria Scandinavia 1 January – 30 September 2013

	Q3	Q3	Q1–Q3	Q1–Q3
EUR million	2013	2012	2013	2012	2012
Net sales	99.7	100.1	292.0	284.6	387.8
EBIT	4.7	4.4	6.5	6.3	8.2
EBIT, %	4.7	4.3	2.2	2.2	2.1
Non-recurring items*	-0.9	0.0	-0.9	0.0	0.0

*Non-recurring items which are included in the reported EBIT.

Atria Scandinavia's net sales for July–September totalled EUR 99.7 million (EUR 100.1 million), down by EUR 0.4 million year-on-year. In the local currencies, net sales grew by 2.8 per cent year-on-year. EBIT was EUR 4.7 million (EUR 4.4 million). EBIT includes non-recurring costs of EUR 0.9 million resulting from the impairment of the held for sale Halmstad plant. EBIT without non-recurring costs amounted to EUR 5.6 million (EUR 4.4 million). The positive performance is due to the improved sales structure and stable raw material prices.

Net sales for January–September totalled EUR 292.0 million (EUR 284.6 million). In the local currencies, net sales grew by 1.7 per cent year-on-year. EBIT for January–September was EUR 6.5 million (EUR 6.3 million). EBIT includes non-recurring costs of EUR 0.9 million resulting from the impairment of the held for sale Halmstad plant. EBIT without non-recurring costs amounted to EUR 7.4 million (EUR 6.3 million). Increased marketing efforts at the beginning of the year and more stable raw material prices improved EBIT.

The position of private labels in the Swedish retail sector continues to be strong. Atria's overall market share remained stable. The sales of the new "Lithells världskorv" and "Oskar Lithells finaste" concepts of the Lithells product selection got off to a good start. Several new products were launched within the Deli product selection during the period under review.

Atria Scandinavia's Handprint programme focused on meat raw material traceability. The company continued to develop procedures related to meat procurement in order to verify the origin and traceability of meat.

Atria Russia 1 January – 30 September 2013

	Q3	Q3	Q1–Q3	Q1–Q3
EUR million	2013	2012	2013	2012	2012
Net sales	32.0	33.9	90.8	93.5	126.3
EBIT	-16.4	0.6	-19.1	-4.7	-8.6
EBIT, %	-51.2	1.8	-21.1	-5.0	-6.8
Non-recurring items*	-15.4	0.0	-15.4	0.0	0.0

*Non-recurring items which are included in the reported EBIT.

Atria Russia's net sales for July–September totalled EUR 32.0 million (EUR 33.9 million). In the local currency, net sales grew by 2.8 per cent year-on-year. EBIT was EUR -16.4 million (EUR 0.6 million). EBIT without nonrecurring costs amounted to EUR -0.9 million (EUR 0.6 million). EBIT without non-recurring costs for July– September was negative due to the poor profitability of primary production.

Net sales for January–September totalled EUR 90.8 million (EUR 93.5 million). EBIT was EUR -19.1 million (EUR -4.7 million). EBIT without non-recurring costs amounted to EUR -3.7 million (EUR -4.7 million). The result for industrial operations improved thanks to efficiency improvement measures. EBIT without non-recurring costs was negative due to the poor profitability of primary production.

Atria Russia will discontinue its unprofitable primary pork production in Russia. Furthermore, the industrial production and logistics unit located in Moscow will be discontinued by the end of 2014. Atria Russia recognised non-recurring impairments totalling EUR 23.0 million, EUR 15.4 million of which was allocated to EBIT. Of the write-downs, EUR 14.3 million was allocated to fixed assets, EUR 7.6 million to deferred tax assets and EUR 1.1 million to other assets. It is estimated that the discontinuation of operations will generate annual cost savings of about EUR 6 million compared to 2013. The cost savings will be fully realised as of the beginning of 2015.

During the period under review, Atria sold its minority share in OOO Dan-Invest, a piggery company operating in Russia. Atria's holding in the company was 26 per cent. The deal had no major impact on Atria's financial position or performance.

The discontinuation of primary pork production will have no impact on Atria Russia's access to meat raw material. Atria Russia's meat product industry uses both meat produced in Russia and imported meat.

	Q3	Q3	Q1–Q3	Q1–Q3
EUR million	2013	2012	2013	2012	2012
Net sales	8.5	8.4	25.0	25.4	34.2
EBIT	0.3	-0.4	-0.1	-1.3	-1.5
EBIT, %	3.6	-4.2	-0.2	-5.0	-4.4
Non-recurring items*	0.0	0.0	0.0	0.0	0.0

*Non-recurring items which are included in the reported EBIT.

Atria Baltic's net sales for July–September totalled EUR 8.5 million (EUR 8.4 million). EBIT was EUR 0.3 million (EUR -0.4 million). During the period under review, retail sales accounted for a greater proportion of total sales than previously. The sales of consumer-packed meat fared particularly well in the summer season.

Net sales for January–September totalled EUR 25.0 million (EUR 25.4 million). EBIT for January–September was EUR -0.1 million (EUR -1.3 million), up by EUR 1.2 million year-on-year. The positive performance is due to the improved sales structure and the cost savings resulting from efficiency improvement measures.

Financing, cash flow, investments and equity ratio

In March, Atria issued a fixed-interest bond worth EUR 50 million. The funds were used for refinancing and for the Group's general financing needs. The loan period is five years and a coupon rate of 4.375 per cent is payable on the loan. The bonds are publicly traded on the NASDAQ OMX Helsinki Ltd stock exchange.

In June, Atria refinanced a committed credit facility of EUR 50 million due in September 2015. The maturity of the new credit facility is five years.

In September, Atria reduced the amount of committed credit facilities by a total of EUR 50 million by discontinuing a credit facility of EUR 40 million due in November 2014 and by refinancing a credit facility of EUR 50 million due in September 2015 with a new credit facility of EUR 40 million.

On 30 September 2013, the amount of the Group's undrawn committed credit facilities stood at EUR 147.3 million (31 December 2012: EUR 153.0 million). The average maturity of loans and committed credit facilities at the end of the period under review was 3 years (31 December 2012: 2 years 10 months).

During the period under review, the Group's free cash flow (operating cash flow - cash flow from investments) was EUR 20.7 million (EUR -1.5 million). Interest-bearing net liabilities came to EUR 343.8 million, down by EUR 20.1 million since the turn of the year. The Group's investments during the period under review totalled EUR 29.2 million (EUR 41.2 million). The equity ratio was 40.9 per cent (31 December 2012: 41.5%).

Events after the period under review

On 21 October 2013, Atria decided to discontinue its unprofitable primary pork production in Russia. Furthermore, the industrial production and logistics unit located in Moscow will be discontinued by the end of 2014. Pizza production will be transferred to the Gorelovo plant in St Petersburg, where investments amounting to EUR 4.6 million will be made. Sales in Moscow will continue under the Campomos brand. The impairments resulting from the discontinuation of business operations were recognised for Q3/2013. Atria recognised impairments totalling EUR 23.0 million, EUR 15.4 million of which was allocated to EBIT. Furthermore, EUR 2.0 million will be recognised as a provision for expenses related to the discontinuation of the aforementioned operations and will be allocated to Q4/2013.

On 21 October 2013, Atria lowered its EBIT forecast due to the non-recurring costs of its Russian business operations. The company expects the full-year EBIT for 2013 to be weaker than the previous year's EBIT, which amounted to EUR 30.2 million. The company's EBIT without non-recurring items is expected to be higher than EUR 30.2 million. According to Atria's previous EBIT forecast, the Group's EBIT for 2013 was estimated to be higher than EUR 30.2 million.

On 28 October 2013, the Finnish Competition and Consumer Authority (FCCA) gave its decision to commence phase two proceeding in a deal whereaby Atria Plc acquires Saarioinen Oy's slaughtering, meet cutting and meet procurement operations.

Personnel

The Group had an average of 4,688 employees (4,927) during the period under review. Personnel by business area:

Atria Finland	2,154	(2,057)
Atria Scandinavia	1,044	(1,110)
Atria Russia	1,168	(1,413)
Atria Baltic	322	( 347)

Short-term business risks

Exchange rate fluctuations and the weakening of the meat market may create uncertainty for the Group's performance. Otherwise, no significant changes occurred in Atria Group's short-term business risks compared with the risks described in the financial statements for 2012.

Outlook for the future

Consolidated EBIT was EUR 30.2 million in 2012. In 2013, it is expected to be weaker. The company's EBIT without non-recurring items is expected to be higher than EUR 30.2 million. Net sales are expected to grow in 2013.

Shares

Atria Plc's share capital consists of a total of 28,267,728 shares, divided into 19,063,747 series A shares and 9,203,981 series KII shares. Each series A share entitles its holder to one (1) vote and each series KII share to ten (10) votes. Therefore, Atria Plc's shareholders are entitled to a total of 111,103,557 votes. The company holds 111,312 series A treasury shares.

Valid authorisations to purchase or issue shares and to grant special rights

The General Meeting authorised the Board of Directors to decide, on one or several occasions, on the acquisition of a maximum of 2,800,000 of the company's own series A shares with funds belonging to the company's unrestricted equity, subject to the provisions of the Limited Liability Companies Act regarding the maximum number of treasury shares to be held by a company. The company's own series A shares may be acquired for use as consideration in any acquisitions or other arrangements relating to the company's business, to finance investments, as part of the company's incentive scheme, to develop the company's capital structure, to be otherwise further transferred, to be retained by the company or to be cancelled.

The shares shall be acquired in a proportion other than that of the shareholders' current shareholdings in the company in public trading arranged by NASDAQ OMX Helsinki Ltd at the market price at the moment of acquisition. The shares will be acquired and paid for in accordance with the rules of NASDAQ OMX Helsinki Ltd and Euroclear Finland Oy. The Board of Directors is authorised to decide on the acquisition of treasury shares in all other respects.

The authorisation shall supercede the authorisation granted by the Annual General Meeting on 3 May 2012 to the Board of Directors to decide on the acquisition of the company's own shares and be valid until the closing of the next Annual General Meeting or until 30 June 2014, whichever is first.

The General Meeting authorised the Board of Directors to decide, on one or several occasions, on an issue of a maximum of 12,800,000 new series A shares or on an issue of any series A shares held by the company through a share issue and/or by granting option rights or other special rights entitling holders to shares as referred to in chapter 10, section 1 of the Limited Liability Companies Act. The authorisation may be exercised for the financing or execution of any acquisitions or other arrangements or investments related to the company's business, for the implementation of the company's incentive programme or for other purposes subject to the Board of Directors' decision.

The Board of Directors is also authorised to decide on all terms and conditions of the share issue and of the granting of special rights as referred to in chapter 10, section 1 of the Limited Liability Companies Act. The authorisation thus also includes the right to issue shares in a proportion other than that currently held by the shareholders under the conditions provided by law, the right to issue shares against or without payment and the right to decide on a share issue to the company itself without payment – subject to the provisions of the Limited Liability Companies Act regarding the maximum number of treasury shares to be held by a company.

The authorisation shall supercede the share issue authorisation granted to the Board of Directors by the Annual General Meeting on 3 May 2012 and be valid until the closing of the next Annual General Meeting or until 30 June 2014, whichever is first.

Accounting principles

This interim report has been prepared in accordance with the IAS 34 Interim Financial Reporting standard. Atria has applied the same principles in preparing this interim report as in preparing the 2012 annual financial statements. However, as of 1 January 2013, the Group uses new or revised standards and IFRIC interpretations published by the IASB, included in the accounting principles of the annual financial statements 2012. None of these new or revised standards or interpretations had any impact on the figures presented for the period under review.

The principles and formulas for the calculation of key indicators have not changed, and they are presented in the 2012 annual financial statements. The figures given in this release are rounded to millions of euros, so the combined total of individual figures may differ from the total sum presented. The figures given in the interim report are unaudited.

CONSOLIDATED INCOME STATEMENT

EUR million	7-9/13	7-9/12	1-9/13	1-9/12	1-12/12
Net sales	358.4	341.1	1,050.4	982.9	1,343.6
Cost of goods sold	-311.3	-291.8	-921.2	-857.5	-1 172.5
Gross profit	47.1	49.3	129.2	125.4	171.1
Sales and marketing costs	-23.3	-22.2	-73.9	-69.9	-95.9
Administration costs	-9.5	-10.6	-31.8	-33.0	-44.2
Other operating income	0.8	0.6	3.0	1.8	3.8
Other operating expenses	-17.0	-0.6	-17.4	-2.0	-4.6
EBIT	-1.8	16.6	9.1	22.4	30.2
Finance income and costs	-3.6	-3.5	-11.2	-10.8	-14.7
Income from joint-ventures and associates	0.4	-0.1	1.9	1.3	3.4
Profit before tax	-5.0	13.1	-0.2	12.9	18.9
Income taxes	-10.1	-4.1	-13.0	-8.0	-8.8
Profit for the period	-15.1	8.9	-13.2	4.9	10.1
Profit attributable to:
Owners of the parent	-15.3	8.7	-13.6	4.7	9.8
Non-controlling interests	0.3	0.2	0.4	0.2	0.2
Total	-15.1	8.9	-13.2	4.9	10.1
Basic earnings/share, EUR	-0.54	0.31	-0.48	0.17	0.35
Diluted earnings/share, EUR	-0.54	0.31	-0.48	0.17	0.35

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

EUR million	7-9/13	7-9/12	1-9/13	1-9/12	1-12/12
Profit for the period	-15.1	8.9	-13.2	4.9	10.1
Other comprehensive income after tax:
Items that will not be reclassified to profit or loss
Actuarial loss on post employment
benefit obligations	0.0	0.0	0.0	0.0	-0.4
Items that will be reclassified to
profit or loss when specific conditions are met
Available-for-sale financial assets	0.0	0.0	0.0	0.0	0.0
Cash flow hedging	1.0	-1.0	2.1	-1.2	-1.2
Translation differences	-0.4	5.7	-7.4	9.4	6.9
Total comprehensive income for the period	-14.5	13.7	-18.5	13.1	15.4
Total comprehensive income attributable to:
Owners of the parent	-14.8	13.4	-18.9	12.7	15.1
Non-controlling interests	0.3	0.3	0.4	0.3	0.3
Total	-14.5	13.7	-18.5	13.1	15.4

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

EUR million	30.9.13	30.9.12	31.12.12
Non-current assets
Property, plant and equipment	444.9	475.1	476.1
Biological assets	0.9	1.5	1.5
Goodwill	167.4	169.3	168.5
Other intangible assets	76.5	75.8	78.4
Investments in joint-ventures and associates	13.9	14.5	14.6
Other financial assets	2.2	1.7	1.7
Loans and other receivables	9.7	16.1	11.6
Deferred tax assets	5.3	15.7	15.5
Total	720.8	769.7	768.0
Current assets
Inventories	127.0	117.2	114.3
Biological assets	5.1	6.2	5.5
Trade and other receivables	121.1	184.8	144.8
Cash and cash equivalents	17.2	8.0	6.6
Total	270.4	316.2	271.1
Non-current assets held for sale	2.5	4.5	2.5
Total assets	993.6	1,090.4	1,041.6
Equity and liabilities
EUR million	30.9.13	30.9.12	31.12.12
Equity belonging to the shareholders
of the parent company	403.1	425.9	428.2
Non-controlling interest	3.6	3.2	3.2
Total equity	406.8	429.1	431.4
Non-current liabilities
Interest-bearing financial liabilities	222.4	274.5	264.3
Deferred tax liabilities	46.5	48.0	47.4
Pension liabilities	8.2	7.8	8.1
Other non-interest-bearing liabilities	5.1	7.3	7.6
Total	282.2	337.6	327.4
Current liabilities
Interest-bearing financial liabilities	138.6	151.3	106.1
Trade and other payables	166.1	172.3	176.6
Total	304.6	323.6	282.8
Total liabilities Total equity and liabilities	586.8 993.6	661.3 1,090.4	610.2 1,041.6

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

EUR million		of parent company			Equity belonging to the shareholders				Non- cont	Total equity
	Share ca pit al	Share pre mium	Own sha res	Other reser ves	Inv. non- rest. equity fund	Trans lation diff.	Retain ed earn ings	Total	roll ing inte rests
Equity 1.1.12	48.1	138.5	-1.3	-4.4	110.6	-17.2	144.5	418.8	2.9	421.7
Comprehensive income for the period Profit for the period Other comprehensive income							4.7	4.7	0.2	4.9
Available-for-sale financial assets Cash flow hedging Actuarial loss Translation differences Transactions with owners				0.0 -1.2		9.2	0.0	0.0 -1.2 0.0 9.2	0.1	0.0 -1.2 0.0 9.4
Distribution of dividends							-5.6	-5.6		-5.6
Equity 30.9.12	48.1	138.5	-1.3	-5.6	110.6	-7.9	143.6	425.9	3.2	429.1
Equity 1.1.13	48.1	138.5	-1.3	-5.6	110.6	-10.3	148.3	428.2	3.2	431.4
Comprehensive income for the period Profit for the period Other comprehensive income							-13.6	-13.6	0.4	-13.2
Available-for-sale financial assets Cash flow hedging Actuarial loss Translation differences Transactions				0.0 2.1		-7.4	0.0	0.0 2.1 0.0 -7.4	0.0	0.0 2.1 0.0 -7.4
with owners Distribution of dividends							-6.2	-6.2		-6.2
Equity 30.9.13	48.1	138.5	-1.3	-3.5	110.6	-17.7	128.6	403.1	3.6	406.8

CONSOLIDATED CASH FLOW STATEMENT

EUR million	1-9/13	1-9/12	1-12/12
Cash flow from operating activities
Operating activities	59.6	42.2	119.2
Financial items and taxes	-14.7	-6.5	-19.6
Net cash flow from operating activities	44.8	35.7	99.6
Cash flow from investing activities
Tangible and intangible assets	-27.4	-40.0	-50.4
Acquired subsidiary shares	0.0	0.0	-1.8
Change in non-current receivables	-0.1	0.0	0.9
Change in other investments	3.3	2.8	1.4
Net cash used in investing activities	-24.1	-37.3	-50.0
Cash flow from financing activities
Proceeds from non-current borrowings	50.0	30.0	50.0
Repayments of non-current loans and
changes in current loans	-53.5	-22.0	-94.6
Dividends paid	-6.2	-5.6	-5.6
Net cash used in financing activities	-9.7	2.4	-50.2
Change in liquid funds	11.0	0.9	-0.6
Cash and cash equivalents at beginning of year	6.6	6.6	6.6
Effect of exchange rate changes	-0.3	0.5	0.5
Cash and cash equivalents at end of year	17.2	8.0	6.6

14 (16)

OPERATING SEGMENTS

EUR million	7-9/13	7-9/12	1-9/13	1-9/12	1-12/12
Net sales
Finland	224.8	205.1	660.8	598.1	819.5
Scandinavia	99.7	100.1	292.0	284.6	387.8
Russia	32.0	33.9	90.8	93.5	126.3
Baltic	8.5	8.4	25.0	25.4	34.2
Eliminations	-6.5	-6.3	-18.3	-18.6	-24.2
Total	358.4	341.1	1,050.4	982.9	1,343.6
EBIT
Finland	9.8	12.5	23.8	25.5	36.5
Scandinavia	4.7	4.4	6.5	6.3	8.2
Russia	-16.4	0.6	-19.1	-4.7	-8.6
Baltic	0.3	-0.4	-0.1	-1.3	-1.5
Unallocated	-0.2	-0.6	-2.0	-3.5	-4.4
Total	-1.8	16.6	9.1	22.4	30.2
Investments
Finland	5.9	10.1	19.0	29.4	38.6
Scandinavia	1.7	3.9	7.6	7.0	12.0
Russia	0.8	1.5	2.4	4.5	5.1
Baltic	0.1	0.1	0.2	0.2	0.5
Total	8.5	15.5	29.2	41.2	56.2
Depreciation and write-offs
Finland	6.3	6.3	19.6	19.4	24.8
Scandinavia	2.9	3.1	9.1	9.0	11.9
Russia	16.6	2.6	21.6	7.7	10.4
Baltic	0.6	0.7	1.9	2.2	2.7
Total	26.4	12.7	52.1	38.3	49.8

FINANCIAL ASSETS AND LIABILITIES

Fair value hierarcy:
EUR milloin
Balance sheet items	30.9.13	Level 1	Level 2	Level 3
Non-current assets
Financial assets available for sale	2.2	0.2		2.0
Current assets
Derivative financial instruments	0.1		0.1
Total	2.2	0.2	0.1	2.0
Non-current liabilities
Derivative financial instruments	5.1		5.1
Current liabilities
Derivative financial instruments	0.9		0.9
Total	6.0	0.0	6.0	0.0
Balance sheet items	31.12.12	Level 1	Level 2	Level 3
Non-current assets
Financial assets available for sale	1.7	0.2		1.6
Current assets
Derivative financial instruments	0.1		0.1
Total	1.9	0.2	0.1	1.6
Non-current liabilities
Derivative financial instruments	7.6		7.6
Current liabilities
Derivative financial instruments	3.1		3.1
Total	10.6	0.0	10.6	0.0

There were no transfers between Levels 1 and 2 during the period.

Level 1: Prices listed on active markets for identical assets and liabilities.

Level 2: Fair values can be determined either directly (i.e., as prices) or indirectly (i.e., derived from prices). Level 3: Fair values are not based on verifiable market prices.

Changes in financial instruments belonging to level 3:

Unlisted shares	30.9.13	31.12.12
Opening balance	1.6	1.5
Purchases	0.4	0.1
Decreases		0.0
Closing balance	2.0	1.6

Fair values of financial instruments do not deviate significantly from balance sheet values.

NON-CURRENT ASSETS HELD FOR SALE

EUR million	30.9.13	30.9.12	31.12.12
Finland		1.4	1.4
Scandinavia	1.4
Russia		2.0
Baltic	1.1	1.1	1.1
Total	2.5	4.5	2.5

During the year 2013, the logistics centre located in Forssa was transferred from assets held for sale back to tangible assets. The property will be used in the company's own production. As a result of the reclassification, write-downs in the amount of EUR 1.1 million recognised during earlier financial periods were reversed. This non-recurring profit item has been recognised under "Other operating income".

In addition, the Halmstad plant real estate, which had remained empty after production was moved to the Malmö plant, was classified as an asset held for sale. During the review period value of the real estate has been decreased EUR 0,9 million.

CONTINGENT LIABILITIES

EUR million	30.9.13	30.9.12	31.12.12
Debts with mortgages or other collateral
given as security
Loans from financial institutions	2.8	2.6	3.0
Pension fund loans	5.7	5.8	5.7
Total	8.5	8.4	8.6
Mortgages and other securities given as
comprehensive security
Real estate mortgages	4.0	3.9	4.2
Corporate mortgages	1.4	1.4	1.4
Total	5.4	5.3	5.6
Guarantee engagements not included in the balance sheet
Guarantees	0.6	0.5	0.4

ATRIA PLC Board of Directors

For more information, please contact Juha Gröhn, CEO, Atria Plc. tel. +358 400 684 224.

DISTRIBUTION

Nasdaq OMX Helsinki Ltd Major media www.atriagroup.com

The Interim Report is available on our Web site www.atriagroup.com.